Indeed, nabiximols [a combination of THC and CBD] is licensed for the treatment of spasticity and spasms in multiple sclerosis, with some effects on pain in this condition.143 To this end and with relevance for IBD, a phase 2a clinical trial of olorinab [APD371], a full CB2 agonist, for visceral pain in Crohn’s disease is under way but has not yet reported [ClinicalTrials.gov Identifier: NCT03155945]. This evidence concerns the gene CNR2 and inflammatory bowel disease.